KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-Current Deferred Tax Liability (2018 - 2023)

Vir Biotechnology's Non-Current Deferred Tax Liability history spans 6 years, with the latest figure at $3.3 million for Q1 2023.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 82.36% to $3.3 million in Q1 2023 year-over-year; TTM through Mar 2023 was $3.3 million, a 82.36% decrease, with the full-year FY2022 number at $3.3 million, down 82.36% from a year prior.
  • Non-Current Deferred Tax Liability hit $3.3 million in Q1 2023 for Vir Biotechnology, roughly flat from $3.3 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for VIR hit a ceiling of $18.4 million in Q4 2021 and a floor of $3.3 million in Q4 2020.
  • Historically, Non-Current Deferred Tax Liability has averaged $7.3 million across 5 years, with a median of $3.3 million in 2019.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 466.83% in 2021 and later tumbled 82.36% in 2022.
  • Tracing VIR's Non-Current Deferred Tax Liability over 5 years: stood at $3.3 million in 2019, then dropped by 1.57% to $3.3 million in 2020, then skyrocketed by 466.83% to $18.4 million in 2021, then tumbled by 82.36% to $3.3 million in 2022, then changed by 0.0% to $3.3 million in 2023.
  • Business Quant data shows Non-Current Deferred Tax Liability for VIR at $3.3 million in Q1 2023, $3.3 million in Q4 2022, and $18.4 million in Q3 2022.